Genmab (GMAB) announced that worldwide net trade sales of Darzalex, including sales of the subcutaneous product daratumumab and hyaluronidase-fihj, sold under the tradename Darzalex Faspro in the U.S., as reported by J&J (JNJ) were $14.351B in 2025. Net trade sales were $8.266B in the U.S. and $6.085B in the rest of the world. Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab: Diversified Oncology Pipeline Supports Upside and Maintained Buy Rating Despite EPKINLY Phase 3 Setback
- Genmab price target lowered to $39 from $41 at H.C. Wainwright
- Genmab price target raised to $38.50 from $34.70 at BofA
- Maintaining Buy on Genmab: Epkinly Combination Potential Outweighs Monotherapy Setback
- Genmab: Limited Epkinly Approval Risk and High-Value 2026 Pipeline Catalysts Support Buy Rating